

1 **Leukotriene A₄ hydrolase deficiency protects mice from diet-induced obesity by**
2 **increasing energy expenditure through neuroendocrine axis**

3

4 Hirotugu Uzawa,^{*,†,1} Daisuke Kohno,^{‡,1} Tomoaki Koga,^{*,§} Tsutomu Sasaki,^{‡,¶} Ayako
5 Fukunaka,^{||} Toshiaki Okuno,^{*} Airi Jo-Watanabe,^{*} Saiko Kazuno,[#] Takeshi Miyatsuka,[†]
6 Tadahiro Kitamura,[‡] Yoshio Fujitani,^{||} Hirotaka Watada,[†] Kazuko Saeki,^{*,2} and Takehiko
7 Yokomizo,^{*}

8

9 ^{*} Department of Biochemistry, Graduate School of Medicine, Juntendo University,
10 Bunkyo-ku, Tokyo, Japan

11 [†] Department of Metabolism and Endocrinology, Graduate School of Medicine, Juntendo
12 University, Bunkyo-ku, Tokyo, Japan

13 [‡] Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation,
14 Gunma University, Maebashi-city, Gunma, Japan

15 [§] Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics,
16 Kumamoto University, Chuo-ku, Kumamoto, Japan

17 [¶] Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto
18 University, Sakyo-ku, Kyoto, Japan

19 ^{||} Laboratory of Developmental Biology and Metabolism, Institute for Molecular and Cellular
20 Regulation, Gunma University, Maebashi-city, Gunma, Japan

21 [#] Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo
22 University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

23

24 ¹ These authors contributed equally.

25 ² Correspondence: Department of Biochemistry, Juntendo University Graduate School of
26 Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.

27 Email: ksaeki@juntendo.ac.jp

28 Telephone: +81-3-5802-1031

29 Fax: +81-3-5802-5889

30

31 short/running title: LTA₄H protects mice from diet-induced obesity

32

33 **Abbreviations:** BAT, Brown adipose tissue; BMI, body mass index; HFD, high-fat diet;
34 LTA₄H, leukotriene A₄ hydrolase; LTB₄, leukotriene B₄; SD, standard diet; SVF, stromal
35 vascular fraction; UCP1, uncoupling protein 1
36

37 **Summary**

38 Obesity is a health problem worldwide, and brown adipose tissue (BAT) is important for
39 energy expenditure. Here, we explored the role of leukotriene A₄ hydrolase (LTA₄H), a key
40 enzyme in the synthesis of the lipid mediator leukotriene B₄ (LTB₄), in diet-induced
41 obesity. LTA₄H-deficient (LTA₄H-KO) mice fed a high-fat diet (HFD) showed a lean
42 phenotype, and bone-marrow transplantation studies revealed that LTA₄H-deficiency in
43 non-hematopoietic cells was responsible for this lean phenotype. LTA₄H-KO mice
44 exhibited greater energy expenditure, but similar food intake and fecal energy loss. LTA₄H-
45 KO BAT showed higher expression of thermogenesis-related genes. In addition, the plasma
46 thyroid-stimulating hormone and thyroid hormone concentrations, as well as HFD-induced
47 catecholamine secretion, were higher in LTA₄H-KO mice. By contrast, LTB₄ receptor
48 (BLT1)-deficient mice did not show a lean phenotype, implying that the phenotype of
49 LTA₄H-KO mice is independent of the LTB₄/BLT1 axis. These results indicate that LTA₄H
50 mediates diet-induced obesity by reducing catecholamine and thyroid hormone secretion.

51

52 **Keywords**

53 brown adipocyte, uncoupling protein 1, thyroid hormone, noradrenaline, peptidase

54

55 Introduction

56 Obesity is now a pandemic. According to the World Health Organization, more
57 than 1 billion adults (about 15% of the world population) are overweight (body mass index
58 [BMI] > 25 kg/m²), and more than 300 million are classified as obese (BMI > 30 kg/m²).
59 Obesity represents a major risk factor for the development of many of the most common
60 diseases, including type 2 diabetes mellitus, dyslipidemias, non-alcoholic fatty liver
61 disease, cardiovascular disease, Alzheimer's disease, and some cancers (1). Therefore,
62 there is a great need for strategies for the prevention and treatment of overweight and
63 obesity. There are various ways of losing weight, including reducing food intake, reducing
64 the intestinal absorption of nutrients, and increasing energy expenditure. Brown adipose
65 tissue (BAT) is a metabolically active tissue that contributes to energy expenditure.
66 Specifically, it dissipates stored chemical energy in the form of heat, its mass inversely
67 correlates with BMI, and it is considered to have an anti-obesity role (2, 3). Therefore, the
68 activation of BAT might permit the maintenance or loss of body mass, even if individuals
69 continue to consume a lipid-rich diet (4). Uncoupling protein 1 (UCP1) is essential for
70 thermogenesis in both brown and beige adipocytes (5), and its activity contributes to the
71 regulation of energy balance (6). A few reports are available for understanding the
72 relationship between lipid mediators and metabolism. These reports show that some lipid
73 mediators regulate glucose tolerance and insulin resistance through inflammation in
74 metabolic tissues, such as liver and adipose tissue (7, 8). However, there are few reports
75 about the role of lipid mediators on obesity (9).

76 Our laboratory has been working on the *in vivo* roles of lipid mediators for a long
77 time, especially leukotriene B₄ (LTB₄). LTB₄ is produced by leukotriene A₄ hydrolase
78 (LTA₄H) from arachidonic acid in hematopoietic cells, and exerts its effects by binding to
79 the high-affinity LTB₄ receptor (BLT1) (10). BLT1 is expressed in inflammatory
80 leukocytes such as neutrophils, eosinophils, effector T-cells, and subsets of macrophages
81 and dendritic cells, and it plays important roles in inflammation (11). During the early
82 phase of inflammation, LTB₄ is generated by LTA₄H in activated leukocytes and attracts
83 other leukocytes, which express BLT1, to sites of inflammation. In relation to metabolism,
84 LTB₄/BLT1 axis promotes inflammation in adipose tissue, liver, and skeletal muscle in

85 mice (12, 13). Although there have been many studies of the roles of BLT1 and LTB₄,
86 which used BLT1 antagonists and BLT1-deficient (BLT1-KO) mice, only a few *in vivo*
87 studies of the roles of LTA₄H have been conducted (14, 15). LTA₄H is expressed not only
88 in hematopoietic cells but also in the other cells than hematopoietic cells. LTA₄H-deficient
89 (LTA₄H-KO) mice, which were generated as early as 1999, used in an experimental model
90 of peritonitis, and there was not reported in metabolic phenotype (16). As we are interested
91 in the relationship between LTA₄H and metabolism, we originally generated LTA₄H-KO
92 mice on C57BL/6 background and found the lean phenotype of this mouse. Here, we
93 clarified the roles of LTA₄H in a high-fat diet (HFD)-induced obesity. Our experiments
94 unveiled the significant relationship between LTA₄H and metabolism, which might help us
95 to develop novel therapeutic methods for obesity.
96

97 **Materials and Methods**

98 *Mice*

99 BLT1-KO (*Ltb4r1*^{-/-}) mice were generated as previously described (17). LTA₄H-KO
100 (*Lta4h*^{-/-}) mice were generated using the CRISPR/Cas9 system on a C57BL/6 background
101 and the details will be reported in another paper (Koga et al., submitted). All experiments
102 were performed using male mice. LTA₄H-KO and BLT1-KO mice were compared with
103 their WT littermates. The mice were housed with free access to food (SD; CRF-1 [Oriental
104 Yeast, Itabashi, Tokyo, Japan] or a 60% HFD [D12492; Research Diets, NJ, USA]) and
105 drinking water in a specific pathogen-free facility. The body mass of the LTA₄H-KO and
106 BLT1-KO mice was measured every week. All animal experiments were approved by the
107 Ethics Committees for Animal Experiments of Juntendo University School of Medicine,
108 and were performed according to appropriate guidelines and regulations.

109

110 *Measurement of food intake*

111 Mice at 7 weeks of age were acclimated to the use of multi-feeders (Shinfactory, Higashi,
112 Fukuoka, Japan) for 1 week. Food intake was measured daily. During this measurement
113 period, mice were housed in individual cages.

114

115 *Measurement of the nutrient energy in feces*

116 Dried feces from mice fed the HFD were collected and used to measure the residual
117 nutrient energy content by direct calorimetry at the Chemicals Evaluation and Research
118 Institute, Japan.

119

120 *Histological analysis*

121 Mouse tissues were dissected, rinsed with phosphate-buffered saline (PBS), fixed in 4%
122 formaldehyde or paraformaldehyde in phosphate buffer, and embedded in paraffin blocks.
123 Tissue sections (4 μm thickness) were stained with H&E.

124

125 *Body composition analysis using micro-computed tomography (CT)*

126 CT was performed under isoflurane anesthesia using a LaTheta micro-CT scanner (Hitachi,
127 Chiyoda, Tokyo, Japan). The abdominal region between the first and sixth lumbar vertebrae
128 was scanned, and the sizes of the fat and soft tissue compartments were measured.

129

130 *Indirect calorimetry*

131 VO_2 and VCO_2 were measured in individual mice at the indicated ages using an Oxymax
132 apparatus (Columbus Instruments, Columbus, OH, USA). The O_2 and CO_2 measurements
133 were performed every 18 min over a 3-day period, during both the light and dark phases,
134 and the data from the final day were analyzed.

135

136 *Measurement of lipid droplet area in the liver and BAT*

137 The size of the lipid droplets (μm^2) was measured using ImageJ software (NIH, Bethesda,
138 MD, USA).

139

140 *qRT-PCR*

141 RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was
142 synthesized using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Nordrhein-
143 Westfalen, GER). Real-time PCR analysis was performed using the LightCycler 96 (Roche
144 Diagnostics, Indianapolis, IN, USA) and FastStart Essential DNA Green Master Mix
145 (Roche Diagnostics), according to the manufacturer's protocol. The sequences of primers
146 used are listed in **Supplemental Table S1**.

147

148 *Bone marrow transplantation studies*

149 Bone marrow cells were collected from the femora, tibiae, and humeri of donor mice, and
150 mature T-lymphocytes were depleted in these using biotinylated anti-CD5 antibody
151 (BioLegend, San Diego, CA, USA) and streptavidin beads (Miltenyi Biotec, Bergisch
152 Gladbach, Nordrhein-Westfalen, GER), to prevent acute graft-versus-host disease.

153 Recipient mice (7–10 weeks of age) were irradiated (9 Gy) and transplanted with $6.5\text{--}8.0 \times$
154 10^6 of these bone marrow cells by injection into the retro-orbital venous plexus.

155 Subsequently, the mice were fed the SD until they were 15 weeks of age, and then from 15
156 to 27 weeks of age they were fed the HFD and were weighed every week.

157 *Separation of the SVF from BAT and its differentiation to yield brown adipocytes*

158 Interscapular BAT was excised from mice, minced with scissors, suspended in 10 mL PBS
159 containing 1.5 U/mL collagenase D and 2.4 U/mL dispase II, and digested at 37°C, with
160 constant agitation at 150 rpm for 40 min. The cell suspension was then filtered through a 70
161 µm cell strainer and centrifuged at $700 \times g$ for 10 min. The cell pellet (the SVF) was re-
162 suspended in 10 mL DMEM/F12 (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine
163 serum (FBS), seeded into a collagen-coated 10 cm dish (Iwaki, Haibara, Shizuoka, Japan),
164 and incubated for 5 days. The cells were then detached and seeded into a collagen-coated
165 12-well plate (1.6×10^5 cells/well) and differentiated into brown adipocytes by incubation
166 in induction medium (DMEM/F12 medium containing 10% FBS, 100 U/mL penicillin, 100
167 µg/mL streptomycin, 861 nM insulin, 1 nM T3, 125 µM indomethacin, 2 µg/mL
168 dexamethasone, 500 µM isobutylmethylxanthine, and 0.5 µM rosiglitazone) for 2 days,
169 followed by incubation in maintenance medium (DMEM/F12 medium containing 10%
170 FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 861 nM insulin, 1 nM T3, and 0.5 µM
171 rosiglitazone) for a further 2 days. The cells were then maintained in a medium containing a
172 high concentration of rosiglitazone (DMEM/F12 medium containing 10% FBS, 100 U/mL
173 penicillin, 100 µg/mL streptomycin, 861 nM insulin, 1 nM T3, and 1 µM rosiglitazone) for
174 3 days. Seven days after the start of the differentiation process, fully differentiated brown
175 adipocytes were stimulated with 10 µM isoproterenol for 1, 6, or 24 hours.

176

177 *Measurement of urine catecholamine concentration*

178 Twenty-four-hour urine collection was performed using bottles containing 1.2 mL of 1N
179 HCl. The collected samples were filled up to 3 mL with deionized water and stored at
180 -80°C until analysis. Urinary catecholamine concentration was measured using high-
181 performance liquid chromatography at the Japan Institute for the Control of Aging, Nikken
182 SEIL Co., Ltd.

183

184 *Measurement of plasma thyroid hormone concentration*

185 The plasma concentrations of TSH, T3, and T4 were measured using a Milliplex thyroid
186 hormone panel kit (Millipore, Billerica, MA, USA) and a Luminex 200 analyzer
187 (Millipore).

188

189 *Flow cytometry*

190 Peripheral blood leukocytes from WT and LTA₄H-KO mice (Ly 5.2) transplanted with WT
191 bone marrow cells (Ly 5.1) were stained with allophycocyanin (APC)-conjugated anti-CD
192 45.1 and phycoerythrin (PE)-conjugated anti-CD 45.2 antibodies. These cells were
193 analyzed using a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA), and the
194 data were analyzed using FlowJo software (Becton, Dickinson, Franklin Lakes, NJ, USA).

195

196 *Statistical analysis*

197 All data were analyzed using GraphPad Prism software (GraphPad, San Diego, CA, USA).
198 The statistical tests used for each analysis are listed in the respective figure legends.

199

200 *Data and code availability*

201 This study did not generate datasets or codes.

202

203 **Results**

204 ***LTA₄H deficiency protects mice from high-fat diet-induced obesity***

205 To investigate the roles of LTA₄H in metabolism, we first monitored the growth of wild-
206 type (WT) and LTA₄H-KO mice. Because LTA₄H-KO mice showed a slightly lean
207 phenotype compared with their WT littermates while eating a standard diet (SD) (**Fig. 1A**),
208 we challenged a group of mice with the HFD after weaning (4 weeks of age). Whereas WT
209 mice showed obvious gains in body mass, these gains were significantly lower in LTA₄H-
210 KO mice (**Fig. 1A**). Next, we determined the effect of LTA₄H deficiency in metabolic
211 tissues. In 27-week-old mice, HFD-induced liver hypertrophy was ameliorated by LTA₄H-
212 deficiency (**Fig. 1B, C**). We analyzed the histology of the liver and BAT of LTA₄H-KO
213 mice, and found that there were smaller lipid droplets in the liver and BAT in LTA₄H-KO
214 mice than in WT mice (**Fig. 1D, E**). We next evaluated the body composition of 12-week-

215 old mice using micro-CT. There was no significant difference in adipose tissue weight, and
216 body fat percentage between LTA₄H-KO and WT mice fed the SD (**Fig. 1F**). Therefore, we
217 challenged a group of mice with the HFD and found that 12-week-old LTA₄H-KO mice
218 were slightly leaner than WT mice of the same age when they had been fed the HFD.
219 Whereas the lean body masses of LTA₄H-KO and WT mice were comparable, the body fat
220 percentage of LTA₄H-KO mice was lower than that of WT mice (**Fig. 1G**).

221

222 *LTA₄H deficiency protects mice from diet-induced obesity by stimulating energy* 223 *expenditure*

224 To determine whether the lean phenotype of the LTA₄H-KO mice is due to lower food
225 intake, we compared the food intake of HFD-fed LTA₄H-KO and WT mice for 3 weeks,
226 and found that there was no difference (**Fig. 2A**). We also measured the energy lost in the
227 feces, and found that this was comparable between LTA₄H-KO and WT mice (**Fig. 2B**). In
228 addition, we performed histological analysis of the small intestine, and found no detectable
229 morphological differences between WT and LTA₄H-KO mice (**Fig. 2C**). Therefore, we
230 concluded that the lean phenotype of the LTA₄H-KO mice is not due to lower food intake
231 or nutrient absorption. We next hypothesized that the lean phenotype might be the result of
232 higher energy expenditure. To test this hypothesis, we evaluated the basal metabolism of
233 LTA₄H-KO mice. We found no significant difference in energy expenditure assessed using
234 oxygen consumption (VO₂) and carbon dioxide production (VCO₂), between LTA₄H-KO
235 and WT mice fed the SD (**Fig. 2D**). On the other hand, the levels of VO₂, VCO₂, and
236 locomotor activity of LTA₄H-KO mice were higher than those of WT mice fed the HFD
237 (**Fig. 2E**). These results suggest that LTA₄H deficiency protects mice from diet-induced
238 obesity by increasing energy expenditure.

239

240 *LTA₄H deficiency stimulates BAT thermogenesis through neuroendocrine axis*

241 According to the results of a previous study (18) and NCBI database
242 (<https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=16993>),
243 LTA₄H is ubiquitously expressed, but its expression is particularly high in hematopoietic
244 cells. We found that LTA₄H is also highly expressed in lymphoid organs, such as spleen

245 and intestine, and that it is expressed in metabolic tissues, such as BAT (**Supplemental**
246 **Fig. S1**). To determine which LTA₄H-expressing cells contribute to the metabolic
247 phenotype, we performed a bone marrow transplantation study. LTA₄H-KO mice that
248 received WT bone marrow exhibited lower body mass gain upon the HFD feeding (**Fig.**
249 **3A**), whereas the body mass gains of recipient mice transplanted with WT or LTA₄H-
250 deficient bone marrow were comparable (**Fig. 3B**). The body mass data are shown in
251 **Supplemental Fig. S2A, B**. Approximately 95% of the bone marrow was replaced in each
252 case (**Supplemental Fig. S2C**). These results show that LTA₄H in non-hematopoietic cells
253 contributes to the metabolic phenotype. BAT is well known to be a diet-induced
254 thermogenic tissue; therefore, we measured the expression of thermogenesis-related genes
255 in the BAT of LTA₄H-KO mice. The expression of brown adipocyte-specific markers, such
256 as *Ucp1*, *Ppara*, *Cidea*, and *Pgc1b*, in BAT was higher in LTA₄H-KO than in WT mice
257 (**Fig. 3C**), but the expression of adipocyte-specific markers, such as *Adipoq*, in epididymal
258 white adipose tissue (eWAT) did not differ between the sets of mice (data not shown).
259 These data suggest that the thermogenic activity of BAT is higher in LTA₄H-KO mice fed
260 the HFD than in WT mice, which may explain the lean phenotype of the LTA₄H-KO mice.
261 The *Ucp1* expression in BAT was also higher in young LTA₄H-KO mice (12 weeks of age)
262 fed the HFD, but not in those fed the SD (**Fig. 3D**). These data indicate that LTA₄H
263 deficiency increases BAT metabolism in response to the HFD feeding. We next isolated the
264 stromal vascular fraction (SVF) of the BAT from LTA₄H-KO and WT mice, induced its
265 differentiation into brown adipocytes, and measured the expression of thermogenesis-
266 related genes. We found no differences in the expression of *Pparg*, *Ndl*, and *Cox1* between
267 primary brown adipocytes derived from LTA₄H-KO and WT mice (**Fig. 3E**), which
268 indicates that LTA₄H-deficiency does not affect the differentiation of brown adipocytes. To
269 evaluate the responsiveness of primary brown adipocytes to a beta-adrenergic receptor
270 agonist, we quantified the expression of the thermogenesis-related gene *Ucp1* before and
271 after stimulation with the non-selective beta-agonist isoproterenol. We found no difference
272 in isoproterenol-induced *Ucp1* expression between LTA₄H-deficient and WT brown
273 adipocytes (**Fig. 3F**). These results suggest that the high expression of thermogenesis-
274 related genes in LTA₄H-deficient BAT *in vivo* is not a brown adipocyte-autonomous

275 phenomenon. Next, we compared the concentrations of hormones with metabolic effects in
276 the plasma and urine of WT and LTA₄H-KO mice. In particular, pituitary and thyroid
277 hormones, and catecholamines, are known to increase *Ucp1* expression in BAT (19). The
278 plasma thyroid-stimulating hormone (TSH) and thyroxine (T₄) concentrations in LTA₄H-
279 KO mice were higher than those in WT mice, but the plasma triiodothyronine (T₃)
280 concentrations were comparable (**Fig. 3G**). These results suggest that LTA₄H deficiency is
281 associated with higher TSH secretion, which stimulates the release of T₄, causing the
282 greater energy expenditure. Next, we compared the effect of switching the mice from the
283 SD to HFD on their urinary noradrenaline concentration, and found that this was greater in
284 LTA₄H-KO mice (**Fig. 3H**). Catecholamine secretion from the adrenal gland is regulated
285 by sympathetic nerves; therefore, these findings suggest that greater energy expenditure in
286 LTA₄H-KO mice may be caused by greater secretion of adrenal hormones, secondary to
287 sympathetic nerve activation.

288

289 ***LTA₄H deficiency protects mice from diet-induced obesity independently of LTB₄/BLT1***
290 ***axis***

291 To determine whether this lean phenotype is caused by defective LTB₄ synthesis and a
292 resultant reduction in BLT1 activation, we monitored the growth of WT and BLT1-KO
293 mice. To our surprise, the BLT1-KO mice did not show a lean phenotype under either the
294 SD or HFD fed conditions (**Fig. 4A**). We could not find any significant difference in liver
295 and BAT between BLT1-KO and WT mice. (**Fig. 4B, C**). Furthermore, there was no
296 significant difference in body composition between HFD-fed BLT1-KO and WT mice (**Fig.**
297 **4D**). These data indicate that the lean phenotype of the LTA₄H-KO mice is not dependent
298 on the LTB₄/BLT1 axis.

299

300

301 Discussion

302 In contrast to the numerous reports on the phenotypes of BLT1-KO mice in various
303 disease models (11, 20), almost nothing is known about *in vivo* roles of LTA₄H. The study
304 of LTA₄H commenced with protein purification and cDNA cloning as early as the 1980s
305 (15, 21). LTA₄H-KO mice were reported to exhibit milder peritonitis than WT mice
306 following zymosan A injection in 1999, but no further investigations were conducted until
307 2010. In addition to its LTB₄ biosynthetic activity, LTA₄H has an aminopeptidase activity
308 that was demonstrated using synthetic peptides (22-24). However, the endogenous substrate
309 for this aminopeptidase activity was not identified for a long time. Snelgrove et al. reported
310 that acute lung injury in LTA₄H-KO mice is exacerbated by impaired degradation of the
311 collagen-derived inflammatory peptide proline-glycine-proline (PGP), which suggested that
312 PGP is an endogenous substrate of the LTA₄H aminopeptidase (25, 26). However, these
313 studies used LTA₄H-KO mice on a 129/SvEv background, which is not suitable for the
314 study of various disease models. Therefore, we created LTA₄H-KO C57BL/6 mice for the
315 study of the *in vivo* roles of LTA₄H (Koga et al., submitted). During the maintenance of
316 these LTA₄H-KO mice, we noticed that aged LTA₄H-KO mice were slightly leaner than
317 their WT littermates, which prompted us to analyze the roles of LTA₄H in metabolism.

318 This is the first study to show the involvement of LTA₄H in diet-induced obesity.
319 Because the lean phenotype of LTA₄H-KO mice was not observed in BLT1-KO mice, we
320 hypothesized that the aminopeptidase activity of LTA₄H is important in diet-induced
321 obesity, and we tried to generate mice that were deficient only in the aminopeptidase
322 activity of LTA₄H. According to previous reports, the amino acid residue Glu-297 of
323 LTA₄H is crucial for its aminopeptidase activity but not for its LTB₄-synthesizing activity.
324 *In vitro* studies showed that the LTA₄H mutant E297Q was still capable of generating LTB₄
325 but did not possess an aminopeptidase activity (27, 28). Therefore, we established two lines
326 of LTA₄H E297Q-knock in (LTA₄H E297Q-KI) mice to determine the roles of the LTA₄H
327 aminopeptidase activity *in vivo*. We were able to confirm the loss of the aminopeptidase
328 activity of LTA₄H in these LTA₄H-KI mice and to reproduce the lean phenotype (data not
329 shown). However, the LTB₄ synthesis in the bone marrow-derived dendritic cells (BMDCs)
330 from these LTA₄H-KI mice was only 10% of that in WT BMDCs (data not shown), and

331 therefore we could not conclude that the loss of the aminopeptidase activity of LTA₄H is
332 responsible for the lean phenotype of the LTA₄H-KO and LTA₄H E297Q-KI mice.

333 LTA₄H deficiency resulted in an amelioration of HFD-induced obesity, which was
334 accompanied by greater energy expenditure and higher expression of thermogenesis-related
335 genes. A bone marrow transplantation experiment showed that LTA₄H expression in non-
336 hematopoietic cells is responsible for this metabolic phenotype. We next measured the
337 expression of LTA₄H in various tissues in mice, and found the highest level of expression
338 in the spleen and intestine, followed by BAT (**Supplemental Fig. S1**). Therefore, we
339 explored the roles of LTA₄H in BAT using LTA₄H-KO mice. We isolated the SVF from
340 interscapular BAT, differentiated the cells into brown adipocytes *in vitro*, and measured the
341 expression of brown adipocyte differentiation markers and the response to catecholamines.
342 The expression of brown adipocyte differentiation markers (*Pparg*, *Ndl*, and *Cox1*) and the
343 isoproterenol-induced upregulation of *Ucp1* mRNA were comparable between WT and
344 LTA₄H-KO mice (**Fig. 3E, F**). Because an analysis of brown adipocytes alone could not
345 explain the difference in phenotype between the WT and LTA₄H-KO mice, we measured
346 the concentrations of several hormones that regulate energy expenditure in BAT. The
347 plasma concentrations of TSH and T4 were higher in LTA₄H-KO than in WT mice (**Fig.**
348 **3G**), and the secretion of noradrenaline was greater in HFD-fed LTA₄H-KO than WT mice
349 (**Fig. 3H**). Although LTA₄H is expressed in the hypothalamus, pituitary, thyroid, and
350 adrenal gland (<https://www.proteinatlas.org/ENSG00000111144-LTA4H/tissue>), no reports
351 are available on the relationship between the neuroendocrine axis and LTA₄H. Elevated
352 levels of TSH, T4, and noradrenaline can explain the lean phenotype of LTA₄H-KO mice.

353 In summary, we identified a novel role for LTA₄H in metabolism, although the
354 detailed molecular mechanism involved has yet to be determined. Considering the fact that
355 this enzyme is widely expressed in tissues and cells, there are several experiments that
356 would provide additional information regarding its roles in metabolism and energy
357 expenditure. First, the generation of cell type-specific LTA₄H-KO mice would be of
358 interest. Second, a denervation study to clarify the relationships between the thyroid gland,
359 adrenal gland, and sympathetic nerves would also clarify the mechanisms involved. Third,
360 experiments aimed at determining the roles of the aminopeptidase activity of LTA₄H in

361 obesity would be of great interest. LTA₄H inhibitors are currently being developed (29-31),
362 and LTA₄H inhibition might increase HFD-induced thermogenesis, which would make it a
363 promising therapeutic target for obesity.

364

365 **Acknowledgments**

366 We thank the Laboratories of Proteomics and Biomolecular Science, Morphology and
367 Image Analysis, Biomedical Research Resources, and Molecular and Biochemical
368 Research at Juntendo University for technical support. This work was carried out by the
369 Joint Research Program of the Institute for Molecular and Cellular Regulation, Gunma
370 University. This work was supported by MEXT/JSPS KAKENHI grants (nos. JP18K06923
371 [to KS], JP17K08664 [to TKoga], JP19K07357 [to TO], JP18K15051 [to AJ], and
372 JP15H05904, JP15H05897, JP18H02627, and JP19KK0199 [to TY]); AMED-CREST (no.
373 JP20gm1210006); the Ono Medical Research Foundation; the Takeda Science Foundation;
374 a Grant-in-Aid (no. S1311011) from the Foundation of Strategic Research Projects in
375 Private Universities from the MEXT; and an Institutional Grant for Environmental and
376 Gender-Specific Medicine to Juntendo University School of Medicine. The authors declare
377 no competing interests.

378

379 **Author contributions**

380 H. Uzawa, K. Saeki, T. Koga, T. Miyatsuka, T. Kitamura, Y. Fujitani, H. Watada, and T.
381 Yokomizo designed the experiments. H. Uzawa, K. Saeki, D. Kohno, T. Koga, A.
382 Fukunaka, T. Sasaki, and T. Okuno performed the experiments. H. Uzawa, K. Saeki, D.
383 Kohno, T. Koga, T. Sasaki, A. Jo, and S. Kazuno analyzed the data. H. Uzawa, K. Saeki,
384 and T. Yokomizo wrote the manuscript.

385

386 **References**

- 387 1. Tseng, Y. H., Cypess, A. M., and Kahn, C. R. (2010) Cellular bioenergetics as a target
388 for obesity therapy. *Nat Rev Drug Discov* **9**, 465-482
- 389 2. van Marken Lichtenbelt, W. D., Vanhomerig, J. W., Smulders, N. M., Drossaerts,
390 J. M. A. F. L., Kemerink, G. J., Bouvy, N. D., Schrauwen, P., and Teule, G. J. J.
391 (2009) Cold-Activated Brown Adipose Tissue in Healthy Men. *N. Engl. J. Med.* **360**,
392 1500-1508
- 393 3. Virtanen, K. A., Lidell, M. E., Orava, J., Heglind, M., Westergren, R., Niemi, T.,
394 Taittonen, M., Laine, J., Savisto, N.-J., Enerbäck, S., and Nuutila, P. (2009)
395 Functional Brown Adipose Tissue in Healthy Adults. *N. Engl. J. Med.* **360**, 1518-
396 1525
- 397 4. Stock, M. J. (1989) The role of brown adipose tissue in diet-induced thermogenesis.
398 *Proc. Nutr. Soc.* **48**, 189-196
- 399 5. Golozoubova, V., Hohtola, E., Matthias, A., Jacobsson, A., Cannon, B., and
400 Nedergaard, J. (2001) Only UCP1 can mediate adaptive nonshivering thermogenesis
401 in the cold. *FASEB Journal* **15**, 2048-2050
- 402 6. Feldmann, H. M., Golozoubova, V., Cannon, B., and Nedergaard, J. (2009) UCP1
403 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt
404 from thermal stress by living at thermoneutrality. *Cell Metab.* **9**, 203-209
- 405 7. Yasui, M., Tamura, Y., Minami, M., Higuchi, S., Fujikawa, R., Ikedo, T., Nagata, M.,
406 Arai, H., Murayama, T., and Yokode, M. (2015) The Prostaglandin E2 Receptor EP4
407 Regulates Obesity-Related Inflammation and Insulin Sensitivity. *PLoS One* **10**,
408 e0136304

- 409 8. Syed, I., Lee, J., Moraes-Vieira, P. M., Donaldson, C. J., Sontheimer, A., Aryal, P.,
410 Wellenstein, K., Kolar, M. J., Nelson, A. T., Siegel, D., Mokrosinski, J., Farooqi, I.
411 S., Zhao, J. J., Yore, M. M., Peroni, O. D., Saghatelian, A., and Kahn, B. B. (2018)
412 Palmitic Acid Hydroxystearic Acids Activate GPR40, Which Is Involved in Their
413 Beneficial Effects on Glucose Homeostasis. *Cell Metab.* **27**, 419-427 e414
- 414 9. Fujimori, K., Aritake, K., Oishi, Y., Nagata, N., Maehara, T., Lazarus, M., and Urade,
415 Y. (2019) L-PGDS-produced PGD2 in premature, but not in mature, adipocytes
416 increases obesity and insulin resistance. *Sci Rep* **9**, 1931
- 417 10. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) A G-
418 protein-coupled receptor for leukotriene B4 that mediates chemotaxis. *Nature* **387**,
419 620-624
- 420 11. Yokomizo, T., Nakamura, M., and Shimizu, T. (2018) Leukotriene receptors as
421 potential therapeutic targets. *J. Clin. Invest.* **128**, 2691-2701
- 422 12. Li, P., Oh, D. Y., Bandyopadhyay, G., Lagakos, W. S., Talukdar, S., Osborn, O.,
423 Johnson, A., Chung, H., Maris, M., Ofrecio, J. M., Taguchi, S., Lu, M., and Olefsky,
424 J. M. (2015) LTB4 promotes insulin resistance in obese mice by acting on
425 macrophages, hepatocytes and myocytes. *Nat. Med.* **21**, 239-247
- 426 13. Spite, M., Hellmann, J., Tang, Y., Mathis, S. P., Kosuri, M., Bhatnagar, A., Jala, V.
427 R., and Haribabu, B. (2011) Deficiency of the leukotriene B4 receptor, BLT-1,
428 protects against systemic insulin resistance in diet-induced obesity. *J. Immunol.* **187**,
429 1942-1949
- 430 14. Haeggström, J. Z. (2018) Leukotriene biosynthetic enzymes as therapeutic targets.
431 *Journal of Clinical Investigation* **128**, 2680-2690
- 432 15. Minami, M., Ohno, S., Kawasaki, H., Radmark, O., Samuelsson, B., Jornvall, H.,
433 Shimizu, T., Seyama, Y., and Suzuki, K. (1987) Molecular cloning of a cDNA coding
434 for human leukotriene A4 hydrolase. Complete primary structure of an enzyme
435 involved in eicosanoid synthesis. *J. Biol. Chem.* **262**, 13873-13876
- 436 16. Byrum, R. S., Goulet, J. L., Snouwaert, J. N., Griffiths, R. J., and Koller, B. H. (1999)
437 Determination of the Contribution of Cysteinyl Leukotrienes and Leukotriene B4 in

- 438 Acute Inflammatory Responses Using 5-Lipoxygenase- and Leukotriene A4
439 Hydrolase-Deficient Mice. *J. Immunol.* **163**, 6810-6819
- 440 17. Terawaki, K., Yokomizo, T., Nagase, T., Toda, A., Taniguchi, M., Hashizume, K.,
441 Yagi, T., and Shimizu, T. (2005) Absence of leukotriene B4 receptor 1 confers
442 resistance to airway hyperresponsiveness and Th2-type immune responses. *J.*
443 *Immunol.* **175**, 4217-4225
- 444 18. Ohishi, N., Minami, M., Kobayashi, J., Seyama, Y., Hata, J., Yotsumoto, H., Takaku,
445 F., and Shimizu, T. (1990) Immunological quantitation and immunohistochemical
446 localization of leukotriene A4 hydrolase in guinea pig tissues. *J. Biol. Chem.* **265**,
447 7520-7525
- 448 19. Bianco, A. C., and McAninch, E. A. (2013) The role of thyroid hormone and brown
449 adipose tissue in energy homeostasis. *The Lancet Diabetes & Endocrinology* **1**, 250-
450 258
- 451 20. Saeki, K., and Yokomizo, T. (2017) Identification, signaling, and functions of LTB4
452 receptors. *Semin. Immunol.* **33**, 30-36
- 453 21. Fitzpatrick, F., Haeggstrom, J., Granstrom, E., and Samuelsson, B. (1983)
454 Metabolism of leukotriene A4 by an enzyme in blood plasma: a possible leukotactic
455 mechanism. *Proc. Natl. Acad. Sci. U. S. A.* **80**, 5425-5429
- 456 22. Toh, H., Minami, M., and Shimizu, T. (1990) Molecular evolution and zinc ion
457 binding motif of leukotriene A4 hydrolase. *Biochem. Biophys. Res. Commun.* **171**,
458 216-221
- 459 23. Orning, L., Gierse, J. K., and Fitzpatrick, F. A. (1994) The bifunctional enzyme
460 leukotriene-A4 hydrolase is an arginine aminopeptidase of high efficiency and
461 specificity. *J. Biol. Chem.* **269**, 11269-11273
- 462 24. Tholander, F., Muroya, A., Roques, B. P., Fournie-Zaluski, M. C., Thunnissen, M.
463 M., and Haeggstrom, J. Z. (2008) Structure-based dissection of the active site
464 chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and
465 inhibitor design. *Chem. Biol.* **15**, 920-929
- 466 25. Snelgrove, R. J., Jackson, P. L., Hardison, M. T., Noerager, B. D., Kinloch, A.,
467 Gaggar, A., Shastry, S., Rowe, S. M., Shim, Y. M., Hussell, T., and Blalock, J. E.

- 468 (2010) A critical role for LTA4H in limiting chronic pulmonary neutrophilic
469 inflammation. *Science* **330**, 90-94
- 470 26. Akthar, S., Patel, D. F., Beale, R. C., Peiro, T., Xu, X., Gaggar, A., Jackson, P. L.,
471 Blalock, J. E., Lloyd, C. M., and Snelgrove, R. J. (2015) Matrikines are key regulators
472 in modulating the amplitude of lung inflammation in acute pulmonary infection. *Nat.*
473 *Commun.* **6**, 8423
- 474 27. Minami, M., Bito, H., Ohishi, N., Tsuge, H., Miyano, M., Mori, M., Wada, H., Mutoh,
475 H., Shimada, S., Izumi, T., and et al. (1992) Leukotriene A4 hydrolase, a bifunctional
476 enzyme. Distinction of leukotriene A4 hydrolase and aminopeptidase activities by
477 site-directed mutagenesis at Glu-297. *FEBS Lett.* **309**, 353-357
- 478 28. Wetterholm, A., Medina, J. F., Radmark, O., Shapiro, R., Haeggstrom, J. Z., Vallee,
479 B. L., and Samuelsson, B. (1992) Leukotriene A4 hydrolase: abrogation of the
480 peptidase activity by mutation of glutamic acid-296. *Proc. Natl. Acad. Sci. U. S. A.*
481 **89**, 9141-9145
- 482 29. Stsiapanava, A., Olsson, U., Wan, M., Kleinschmidt, T., Rutishauser, D., Zubarev, R.
483 A., Samuelsson, B., Rinaldo-Matthis, A., and Haeggstrom, J. Z. (2014) Binding of
484 Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and
485 development of an epoxide hydrolase selective inhibitor. *Proc. Natl. Acad. Sci. U. S.*
486 *A.* **111**, 4227-4232
- 487 30. König, S., Pace, S., Pein, H., Heinekamp, T., Kramer, J., Romp, E., Straßburger, M.,
488 Troisi, F., Proschak, A., Dworschak, J., Scherlach, K., Rossi, A., Sautebin, L.,
489 Haeggström, J. Z., Hertweck, C., Brakhage, A. A., Gerstmeier, J., Proschak, E., and
490 Werz, O. (2019) Gliotoxin from *Aspergillus fumigatus* Abrogates Leukotriene B4
491 Formation through Inhibition of Leukotriene A4 Hydrolase. *Cell Chemical Biology*
492 **26**, 524-534.e525
- 493 31. Low, C. M., Akthar, S., Patel, D. F., Loser, S., Wong, C. T., Jackson, P. L., Blalock,
494 J. E., Hare, S. A., Lloyd, C. M., and Snelgrove, R. J. (2017) The development of novel
495 LTA4H modulators to selectively target LTB4 generation. *Sci Rep* **7**, 44449
496
497

498 **Figure legends**

499 **Figure 1. LTA₄H deficiency protects mice from diet-induced obesity. A)** Growth curve
 500 of LTA₄H-KO and WT mice fed a standard diet (SD) or a high-fat diet (HFD) ($n = 10\text{--}16$
 501 mice per group). **B)** Macroscopic appearance of livers from 27-week-old LTA₄H-KO and
 502 WT mice fed the HFD. **C)** Liver masses of LTA₄H-KO and WT mice ($n = 6\text{--}9$ mice per
 503 group). **D, E)** Representative images of hematoxylin and eosin (H&E)-stained histological
 504 sections from LTA₄H-KO and WT mice fed the HFD until 27 weeks of age (D, liver; E,
 505 BAT; upper panels). Quantification of the lipid droplet area ratio (lower left) and lipid
 506 droplet size (lower right) ($n = 6\text{--}9$ mice per group). Scale bars, 100 μm . **F)** Body
 507 composition of 12-week-old control (Ctrl; WT and LTA₄H-hetero) and LTA₄H-KO mice
 508 fed the SD ($n = 9\text{--}10$ mice per group). **G)** Body composition of LTA₄H-KO and WT mice
 509 fed the HFD until 12 weeks of age ($n = 7\text{--}10$ mice per group). Graphs represent means \pm
 510 SEMs (**A, C, and D–G**). Statistical analysis was performed using two-way ANOVA (**A**) or
 511 unpaired Student's *t*-test (**C–G**): ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *n.s.*, not
 512 significant.

513

514 **Figure 2. LTA₄H deficiency protects mice from diet-induced obesity by stimulating**
 515 **energy expenditure. A)** Food intake by LTA₄H-KO and WT mice fed the HFD at 8–11
 516 weeks of age ($n = 6$ mice per group). **B)** Residual energy in the feces of LTA₄H-KO and
 517 WT mice fed the HFD ($n = 3$ mice per group). **C)** Representative images of H&E-stained
 518 small intestinal sections from LTA₄H-KO and WT mice fed the HFD until 12 weeks of age.
 519 Scale bars, 100 μm . **D)** Energy expenditure and locomotor activity of 12-week-old Ctrl and
 520 LTA₄H-KO mice fed the SD ($n = 9\text{--}10$ mice per group). **E)** Energy expenditure and
 521 locomotor activity of LTA₄H-KO and WT mice fed the HFD until 12 weeks of age ($n = 7\text{--}$
 522 10 mice per group). The graphs show the means \pm SEMs (**A, D and E**) and means \pm SDs
 523 (**B**). Statistical analysis was performed using two-way ANOVA (**A**) or unpaired Student's
 524 *t*-test (**B, D and E**): *, $p < 0.05$; *n.s.*, not significant.

525

526 **Figure 3. LTA₄H deficiency stimulates BAT thermogenesis through neuroendocrine**
 527 **axis. A, B)** Body mass gain of mice that had undergone bone marrow transplantation and

528 the HFD feeding between 15 and 27 weeks of age. LTA₄H-KO and WT mice (Ly 5.2)
 529 reconstituted with WT (Ly 5.1) bone marrow (A, $n = 9-12$ mice per group), and WT mice
 530 (Ly 5.1) reconstituted with WT or LTA₄H-KO (Ly 5.2) bone marrow (B, $n = 8-9$ mice per
 531 group), were studied. C) Expression of brown adipocyte-specific marker genes in
 532 interscapular BAT from LTA₄H-KO and WT mice fed the HFD until 24 weeks of age.
 533 Gene expression relative to that of *Actb* is shown ($n = 4$ mice per group). D) Expression of
 534 *Ucp1* in BAT from LTA₄H-KO and WT mice fed the SD or HFD until 12 weeks of age.
 535 The relative expression of *Ucp1* to *Rps18s* is shown ($n = 4$ mice per group) E) Expression
 536 of brown adipocyte-specific marker genes in primary brown adipocytes harvested from
 537 LTA₄H-KO and WT mice at 8 weeks of age. The expression relative to that of *Rps18s* is
 538 shown ($n = 3$). F) Time course of *Ucp1* expression in primary brown adipocytes harvested
 539 from LTA₄H-KO and WT mice before and after isoproterenol stimulation ($n = 7$ for every
 540 time point). G) Plasma TSH, T4, and T3 concentrations in HFD-fed LTA₄H-KO and WT
 541 mice ($n = 8-9$ mice per group) H) 24-hour urinary noradrenaline excretion by LTA₄H-KO
 542 and WT fed the SD or HFD ($n = 8-9$ mice per group). The graphs show the means \pm SEMs
 543 (A, B, and F-H) and means \pm SDs (C-E). Statistical analysis was performed using two-
 544 way ANOVA (A, B and F), unpaired Student's t test (C, E and G), paired Student's t test
 545 (H), or one-way ANOVA (D): ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$; *n.s.*,
 546 not significant.

547

548 **Figure 4. BLT1-KO mice do not show the lean phenotype.** A) Growth curve of BLT1-
 549 KO mice and WT mice fed the SD or HFD ($n = 24-31$ mice for the SD group; $n = 8-10$
 550 mice for the HFD group). B, C) Representative images of H&E-stained histological
 551 sections (B, liver; C, BAT) from 29-week-old BLT1-KO and WT mice fed the HFD. Scale
 552 bars, 100 μ m. D) Body composition of BLT1-KO and WT mice fed the HFD until 12
 553 weeks of age ($n = 7$ mice per group). Graphs represent means \pm SEMs (A and D).
 554 Statistical analysis was performed using two-way ANOVA (A) or unpaired Student's t test
 555 (D): *n.s.*, not significant.

Figure 1




Figure 2




Figure 3





Figure 4



Supplemental Figure




Figure S1. Gene expression of *Lta4h* in various tissues

Expression of the *Lta4h* gene in tissues from 10-week-old WT mice. Expression is shown relative to that of *Rps18s* ($n = 3$ per mice).

Supplemental Figure




Figure S2. LTA₄H expressed in non-hematopoietic cells contributes to the metabolic phenotype

A, B) Growth curves of bone marrow-transplanted mice fed the HFD. LTA₄H-KO and WT mice (Ly 5.2) reconstituted with WT (Ly 5.1) bone marrow cells (**A**, $n = 9–12$ mice per group), and WT mice (Ly 5.1) reconstituted with WT or LTA₄H-KO (Ly 5.2) bone marrow (**B**, $n = 8–9$ mice per group), were studied. The body masses of these mice were measured between 15 and 27 weeks of age. **C**) Representative flow cytometric data for peripheral blood leukocytes from WT (left) and LTA₄H-KO (Ly 5.2) mice (middle) transplanted with WT bone marrow cells (Ly 5.1). The right panel shows the leukocytes from WT (Ly 5.2) mice.